Technology Listings


14 Results Sort By:
Antibody for the Treatment of Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Application Repurposed monoclonal antibody (mAb) that blocks inflammatory CD4 T cell migration for the treatment of NASH and liver fibrosis. Key Benefits Therapy for treating NASH, NAFLD, and liver fibrosis. Potential reduced approval time due to existing clinical safety data for α4β7 mAb. Market Summary Non-alcoholic steatohepa...
Published: 6/24/2019       Inventor(s): Frank Anania, Khalidur Rahman
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making ant...
Published: 6/18/2019       Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
PLK1 Inhibitors for the Diagnosis and Treatment of Small Cell Lung Carcinoma (SCLC)
ApplicationPolo Like Kinase 1 (PLK1) inhibitor as a potent treatment strategy for SCLC patients with a specific TP53 mutation.Key BenefitsA personalized cell therapy for recurrent SCLC cases.Higher efficiency in TP53 mediated PLK1 inhibition to control carcinoma.PLK1, a predictive biomarker for SCLC diagnosis.Market SummaryLung cancer is the most c...
Published: 12/6/2018       Inventor(s): Taofeek Owonikoko
DHAA and Derivatives for Treatment of BRAF-V600E-Positive Cancer
ApplicationHypolipidemic dehydroacetic acid (DHAA) treatment to prevent growth of BRAF V600E positive tumors.Key BenefitsTreatment with slows BRAF V600E-positive tumor growth.Repurposed compound may speed FDA approval.May be used in combination with other therapies.Market SummaryAccording to the American Cancer Society, skin cancer is the most comm...
Published: 10/26/2017       Inventor(s): Jing Chen, Jack Arbiser, Brian Pollack, Siyuan Xia
Repurposed Kinase Inhibitor for Treatment of Multidrug Resistant Tuberculosis
ApplicationProtein tyrosine kinase inhibitor (imatinib) used as a treatment to prevent multiple drug-resistant tuberculosis lethality and latent reactivation.Key BenefitsEffective against drug resistant strains of tuberculosis.May be used in combination with current first-line treatments of TB.Market SummaryTuberculosis (TB) is a chronic infectious...
Published: 6/20/2017       Inventor(s): Daniel Kalman
Repurposed Small Molecules that Promote Osteogenesis
Application Repurposed small molecules for use as a bone forming therapeutic during treatment of diseases requiring local bone formation such as fracture repair, spinal fusion, and large segmental bone defects. Key Benefits Current treatments require high concentrations of bone morphogenetic protein (BMP) which results in high costs, adverse side...
Published: 4/14/2016       Inventor(s): Scott Boden, Sreedhara Sangadala
Repurposed Small Molecules as a Targeted, Combination Therapy for Multiple Myeloma
ApplicationCombination of an inhibitor of glucose metabolism and BH3 mimetic for increased efficacy in the treatment of multiple myeloma.Key BenefitsActivates cell death pathways through independent molecular mechanisms, resulting in enhanced effect with combination therapy. Repurposed use of FDA-approved therapies to expand indications in oncology...
Published: 3/25/2016       Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai, Lawrence Boise
Repurposed Antifibrinolytic Agents as a Substitute for Platelet Transfusions to Prevent Bleeding in Severe Thrombocytopenia Patients
Application Prophylactic administration of an antifibrinolytic agent, epsilon aminocaproic acid (EACA), to prevent bleeding in patients with thrombocytopenia from hematological malignancies. Key Benefits Orally bioavailable, repurposed drug. Commonly used and FDA approved to manage hemorrhage in patients with congenital bleeding. Cheaper and eas...
Published: 4/9/2014       Inventor(s): Hanna Khoury, Ana Antun
Repurposed Kinase Inhibitors as Vaccine Adjuvants
Application Repurposed, small molecule kinase inhibitors, such as epidermal growth factor receptor (EGFR) inhibitors, as topical vaccine adjuvants. Key Benefits Improves immune response and efficacy of vaccines and vaccine candidates. Employs compounds that are already approved for human use. Market Summary In order to create long lasting protec...
Published: 4/8/2014       Inventor(s): Brian Pollack, Richard Compans, Joanna Pulit-Penaloza, Ioanna Skountzou
Combination Drug Treatment for Neoplasms Associated with Tuberous Sclerosis
Application Combination of rapamycin and imatinib for the treatment of neoplasms associated with tuberous sclerosis (TS). Key Benefits Combined therapy shows 97% decrease in tumor volume in mouse model of TS compared to vehicle treatment. Dual therapy blocks two major signaling pathways implicated in TS. Market Summary Tuberous sclerosis (TS) is...
Published: 9/18/2012       Inventor(s): Jack Arbiser
1 2